Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with von Hippel-Lindau disease, which is characterized by the development of highly vascularized tumors. Here, we identified a new VHL cryptic-exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. More importantly, we identified mutations in E1' in seven families with erythrocytosis (one homozygous case and six compound-heterozygous cases with a mutation in E1' in addition to a mutation in VHL coding sequences) and in one large family with typical VHL disease but without any alteration in the other VHL exons. In this study we have shown that the mutations induced a dysregulation of the VHL splicing with excessive retention of E1' and are associated with a downregulation of VHL protein expression. In addition, we have demonstrated a pathogenic role for synonymous mutations in VHL-Exon 2 that alter splicing through E2-skipping in five families with erythrocytosis or VHL disease. In all the studied cases, the mutations differentially impact splicing, correlating with phenotype severity. This study demonstrates that cryptic-exon-retention or exon-skipping are new VHL alterations and reveals a novel complex splicing regulation of the VHL gene. These findings open new avenues for diagnosis and research into the VHL-relatedhypoxia-signaling pathway.
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Abstract:
Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with von Hippel-Lindau disease, which is characterized by the development of highly vascularized tumors. Here, we identified a new VHL cryptic-exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. More importantly, we identified mutations in E1' in seven families with erythrocytosis (one homozygous case and six compound-heterozygous cases with a mutation in E1' in addition to a mutation in VHL coding sequences) and in one large family with typical VHL disease but without any alteration in the other VHL exons. In this study we have shown that the mutations induced a dysregulation of the VHL splicing with excessive retention of E1' and are associated with a downregulation of VHL protein expression. In addition, we have demonstrated a pathogenic role for synonymous mutations in VHL-Exon 2 that alter splicing through E2-skipping in five families with erythrocytosis or VHL disease. In all the studied cases, the mutations differentially impact splicing, correlating with phenotype severity. This study demonstrates that cryptic-exon-retention 
Introduction:
Congenital erythrocytosis represents a heterogeneous group of rare disorders. Genetic changes affecting all parts of the regulatory pathway of erythropoiesis, including oxygen sensing, erythropoietin sensitivity, or hemoglobin oxygen affinity have been described in patients with congenital erythrocytosis. The detection of underlying genetic changes in patients with presumed hematological pathology may have important implications for an adequate clinical management.
However, even with the use of NGS panel diagnostics, the underlying genetic cause of presumed congenital erythrocytosis has been identified in less than one third of the patients in most published cohorts.
The molecular basis of VHL-related congenital erythrocytosis was first described in the autonomous Russian Republic of Chuvashia where this condition is an endemic disorder. 1 Chuvash polycythemia is frequently associated with rubor, vertebral hemangiomas, varicose veins and low blood pressure. Chuvash patients have reduced survival rates associated with a higher prevalence of arterial and venous thromboses and pulmonary hypertension in addition to hemorrhagic events. 2 Chuvash polycythemia arose from a homozygous c.598C > T, p.Arg200Trp (R200W) mutation in the VHL gene. This specific VHL-R200W mutation has also been identified in combination with other VHL mutations (compound-heterozygosity) in Chuvash polycythemia. Subsequently, other missense VHL mutations in both alleles have been described in patients with congenital erythrocytosis. 3, 4 Interestingly, it has been described some unexplained cases of patients with erythrocytosis in which only one heterozygous VHL mutation has been identified to date. [4] [5] [6] VHL is located on 3p25-26 and has been reported to contain three exons (E1, E2, E3). The commonly described VHL transcript contains the three spliced exons that encode a 213 aminoacid (aa) protein (pVHL213 also termed pVHL30) and a smaller isoform (pVHL160 or pVHL19)
initiated from an in-frame internal translation start site. 7 A naturally occurring splice variant, expressed at low levels in some tissues, comprises E1 directly spliced to E3 and is translated into a protein product termed pVHL172 (pVHLΔE2), the functions of which are still under investigation. [8] [9] [10] [11] [12] pVHL213 and pVHL160 are involved in a variety of functions, the most studied being the regulation of the cellular oxygen-sensing pathway. The main player of this pathway is the Hypoxia Inducible Factor (HIF). Under normal oxygen supply, the α−subunits of HIF (HIF-
1α, 2α and 3α) are hydroxylated by the prolyl-4 hydroxylase domain enzymes (PHD1, 2 and 3) and subsequently targeted by pVHL, a subunit of an E3 ubiquitin-ligase complex that promotes HIF-α ubiquitination and subsequent proteasomal degradation. 13, 14 Under hypoxic conditions or when VHL is mutated, HIF-α remains stable and heterodimerizes with HIF-β, constituting a functional HIF factor. HIF transcriptionally activates a variety of genes involved in adaptation to reduced oxygen supply (e.g. erythropoiesis, angiogenesis, metabolism and cell survival).
Dysregulation of the hypoxia pathway 13, 14 is central to the development of erythrocytosis 1,4 (via upregulation of erythropoietin (EPO), a HIF2α target gene), but also in the development of tumors. 15 Indeed, VHL is a tumor suppressor gene, heterozygous mutations of which are associated with von Hippel-Lindau disease ( Figure 1A) . 16, 17 The VHL disease, described in 1936,
is an autosomal dominant disorder with high penetrance characterized by the development of highly vascularized tumors like central nervous system and retinal haemangioblastomas, pancreatic neuroendocrine tumors, pheochromocytomas and clear-cell renal cell carcinomas (ccRCC). [18] [19] [20] In patients carrying VHL mutations, the precise mechanistic aspects that underpin the different phenotypes remain obscure. Although most patients carry mutations in the VHL gene that induce a partial or complete loss of protein function, some cases remain unsolved. Indeed, some patients with erythrocytosis have been found to be heterozygous rather than homozygous for the expected alteration [4] [5] [6] or carry homozygous synonymous mutations that leave the amino-acid sequence intact. In addition, some patients present with VHL disease in the absence of identified mutations or deletions in VHL, or carry heterozygous synonymous mutations. Here, we report an investigation of twelve families linked to unexplained disease, including nine families with erythrocytosis and three families with VHL disease ( Figure 1A ). This study has led to the discovery of a novel cryptic-exon in the VHL gene and a complex regulation of VHL splicing.
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Methods:
Complete materials and methods are detailed in supplemental data.
Study approval
Informed consent for medical diagnosis and research was obtained from the patients and their relatives. This study was agreed by the CCPPRB (French Ethical Committee) Paris-Sud at Bicêtre Hospital.
Sanger sequencing
Exons and exon-intron junctions of the VHL gene were sequenced from DNA extracted from whole blood, as previously described.
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Whole Genome Sequencing
Whole genome sequencing (for Families F2, F3, F7) was performed at the clinically accredited Molecular Diagnostics Laboratory at the John Radcliffe Hospital using the Hi-Seq 4000 platform (Illumina Inc., San Diego, CA) in high-throughput mode. 22, 23 Analysis of single nucleotide variants, short insertions/deletions and copy number variants was conducted and is explained in detail in the supplemental methods.
Transcript detection and quantification
After reverse-transcription reactions (ThermoScientific), exon-specific PCR was performed using primers localized to flanking E1 and E3 exons. Taqman real-time PCR were performed on 20 ng of cDNA with the qPCR Mastermix (Eurogentec). Quantification of RPLP0 transcripts was used as internal control. The thresholds were determined using dilutions of plasmids containing coding sequences of each gene.
RNA sequencing
Library construction was performed with SureSelect Strand-Specific RNA Library Prep for the Illumina Multiplexed-kit (Agilent-Technologies). After purification (Macherey-Nagel), the fragment size of libraries was controlled using the 2200 TapeStation system (Agilent- 24 After 24h, luciferase assays were performed using a Dual-Luciferase®Reporter Assay System (Promega).
Western Blotting
Cell lysates from the luciferase reporter assay were loaded into a Bis-Tris Mini Gel (4-12%) (Invitrogen). After transfert, the membrane (GE-Healthcare) was subsequently incubated with a mouse anti-HA antibody (BioLegend), and then a goat anti-mouse HRP-conjugated antibody (Jackson-Immuno-Research). Western blot using the mouse monoclonal antibody JD-1956 (Patent No. 14305925.1-1402-2014; CNRS-EFS) raised against human VHL was performed as described.
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Minigene experiments
Minigene constructs were prepared in pCas2 plasmid, containing two artificial exons A and B (as described 25 ), between which VHL-Exon1' or VHL-Exon2 with intronic flanking sequences were cloned. Cells were transfected (Polyplus) or nucleofected (Lonza). RNA were extracted 24h after transfection and reverse transcribed. PCR amplification was performed using the PCR GoTaqQ2 kit (Promega) with primers against artificial (A and B) exons. PCR products were resolved in a 2% agarose gel.
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Results:
Identification of new VHL spliced isoforms containing a cryptic-exon.
We first focused our study on a patient with erythrocytosis in whom a synonymous VHL c.429C>T, p.Asp143Asp (D143D) mutation in the heterozygous state had previously been identified (Family 1, Table 1 ). No other mutations in the three VHL canonical exons had been identified in genomic DNA of this patient. A RT-PCR using primers in E1 and E3 was performed using mRNA samples extracted from lymphoblastoid cell lines (LCL) established from different family members. The results showed a strong decrease of the E1E2E3 isoform and an upregulation of the E1E3 isoform ( Figure 1B ) compared with wild-type LCL. Some minor extra fragments of larger size were observed in this patient and his mother's sample. Subcloning and sequencing of these fragments allowed us to identify new VHL transcripts that contained intronic sequences. This intronic sequence, which we termed the E1' cryptic-exon, is spliced to E1 at its 5'
end, and to either E2 or E3 at its 3' terminus ( Figure 1C ). We showed that these isoforms are expressed in a variety of tissues and cell lines (Supplemental Fig.1 ). Their translation may theoretically lead to the production of a protein of 193 aa that contains the first 114 aa encoded by E1 26 , and 79 additional aa of unknown function encoded by E1'. During the course of our study, data from an automated computational analysis for an isoform containing the E1' crypticexon (E1E1'E2 isoform), was deposited in NCBI. This isoform was predicted to encode a protein of 193 aa, named X1 (XP_011532380.1) with the sequence described above. The analysis of this region revealed strong conservation in primates, but a moderate to low conservation in more distant species (Supplemental Fig.2A-C) ; notably, the splice sites are identical to canonical sites (ttcag/TC, AG/gtaag), and are highly conserved. In silico analysis of the donor (SD) and acceptor (SA) splice sites of E1' showed similar consensus values compared to other VHL exons ( Figure   1C , upper panel). The capacity to translate a potential X1 protein is only conserved in higher primates (Supplemental Fig.2D ). The deposited sequence has now been removed and replaced by a non-coding isoform containing E1' spliced with VHL-E2 and E3 (ENST00000477538.1) ( Figure 1C , isoform on the bottom). This isoform may be initiated by an alternative promoter.
Indeed, the sequence located at the 5' end of E1' represents a transcriptionally active region, as illustrated by epigenetic marks (Supplemental Fig.3 ). We confirmed the expression of an additional transcript initiated from the upstream region of E1' (that we termed "Upstream E1'") in different tissues and cell lines (Supplemental Fig.1 ).
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The new E1' cryptic-exon is mutated in patients with erythrocytosis or von Hippel-Lindau disease.
Sanger sequencing of this new cryptic-exon in the proband (F1-II.1) identified a variant which had not been reported in databases: c.340+770T>C ( Figure 2B , Table 1 , Supplemental   Fig.4) . Sequencing of the germline DNA of the mother revealed the same variant, indicating that the propositus F1-II.1 is compound heterozygous. This result prompted us to sequence additional patients with erythrocytosis described as heterozygous for VHL mutations.
We investigated Chuvash polycythemia patients for whom the VHL-R200W had been found in a heterozygous state. Sanger sequencing identified the identical intronic variant c.340+770T>C in a singleton (F2) 5 and two affected brothers (F3) ( Figure 2B ). In addition, we identified a duplication c.340+694_711dup in the proband of F4 and F5 6 previously described as VHL-R200W/wt and VHL-G144R/wt respectively ( Figure 2B ). In F6, previously diagnosed as VHL-Q164H/wt, we identified a genetic variant c.340+574A>T that altered the consensus spliceacceptor (SA) site ag/TC of E1'. This variant is described as a rare polymorphism (rs98274567)
in the NCBI database (Table 1) .
As biological material from the parents of F2 and F3 was not available, we cloned the intronic region containing the E1' variant and the Chuvash core-haplotype SNP (single nucleotide polymorphism) rs779808 associated with the VHL-R200W mutation (described 27 In a parallel independent study, whole genome sequencing (WGS) was being used to investigate patients with Chuvash polycythemia, heterozygous for the VHL-R200W mutation (F2 and F3).
The intronic variant c.340+770T>C was the only rare variant identified in the VHL gene in these patients. Other WGS filtering strategies (Supplemental Methods) did not identify any further significant mutations in biologically relevant genes (Supplemental Fig.6 ). This study also conducted WGS for a trio with congenital erythrocytosis for which prior whole exome sequencing (WES) had not identified any mutations (F7). No rare biologically relevant variants 1 0
were identified using the filtering strategy described in Supplemental Methods. However, further inspection of the new cryptic-exon led to the identification of a c.340+816A>C variant in the homozygous state in the proband, with both parents being heterozygous for this mutation.
In addition to these patients with erythrocytosis, in which no variants in VHL were initially detected, screening of patients with von Hippel-Lindau disease may also fail to detect mutations in canonical VHL exons. An example of such family, F8, with hereditary hemangioblastoma, clear-cell renal-cell carcinoma and pheochromocytoma has been studied. Microsatellite analysis demonstrated a co-segregation of markers surrounding the VHL region with the disease (Supplemental Fig.7) . Sequencing of the new E1' cryptic-exon in this family identified two heterozygous variants in E1': a previously unreported c.340+617C>G variant and a c.340+648T>C variant described as a rare polymorphism in databases (Table 1) . These variants segregate in six patients who developed the disease, and were absent in four healthy tested descendants, indicating their presence on a single disease-associated allele ( Figure 2B ).
Sequencing of tumor DNAs did not display loss of heterozygosity (LOH), suggesting that a wild-
type VHL deletion (as observed in classic VHL disease) may not be prerequisite in cells of patients with this specific VHL genotype (Supplemental Fig.4 ).
Expression study of the new VHL isoforms in patients' cells.
RNA-sequencing (RNA-Seq) analysis of patients' LCL and tumors demonstrated that genomic variants in E1' are associated with an up-regulation of transcripts containing the E1' cryptic-exon compared with controls ( Figure 3A, Supplemental Fig.8 ). In addition, the mutated allele is preferentially expressed (more than 70%), suggesting a causal relationship between the genetic variants and the E1' retention (Supplemental Fig.8C ).
We performed quantitative RT-PCR using TaqMan probes specific for the different splicing junctions or for the region upstream of E1' (location of probes Figure 1C ), which showed a strong upregulation of a unique isoform containing E1' spliced with E1 in LCL and tumors from patients of F8 compared with controls ( Figure 3B ). The study therefore focused on the isoform E1-E1'.
Transcripts that retain E1' spliced with E1 contain (in-frame with E1) a premature termination codon ( Figure 1C ) and are likely targeted for degradation according to nonsense-mediated mRNA Decay (NMD) mechanisms. We therefore investigated the expression of transcripts that 1 1 contain E1 spliced with E1' in the absence or presence of puromycin, an inhibitor of NMD.
Without puromycin, higher levels of expression were seen in samples with mutated E1' ( Figure   3C ) compared with samples containing WT-E1'. Exposure to puromycin resulted in a profound induction of isoforms containing E1 spliced with E1' versus other isoforms ( Figure 3C , Supplemental Fig.9 ). These results indicated that isoforms with E1-E1' junction are degraded by NMD and may fail to produce proteins. We performed RT-PCR on LCL sample of F6 carrying the mutation in the SA site, using primers in VHL exons E1 and E3. We observed fragments of larger size in samples from patients carrying the mutation, which were highly visible in presence of puromycin ( Figure 3D ). Cloning and sequencing of these fragments demonstrated a dysregulated splicing of E1' with the use of an alternative SA site located 15 nucleotides downstream (Supplemental Fig.10 ).
In order to measure the impact of the splicing dysregulation on pVHL expression, we performed an immunoblot with an antibody able to recognize the aa encoded by E1 and, therefore, able to detect the different pVHL isoforms. 8 The antibody detected overexpressed exogenous X1 protein following transfection of plasmid encoding X1 ( Figure 4A ). However, it failed to detect the endogenous protein, even in patients' samples that overexpress the mRNA containing E1-E1'.
Instead, the immunoblots showed a lower expression of all the VHL protein isoforms in patients with mutated E1' (Figures 4A and 4B ).
Functional characterization of the mutated VHL-E1'.
As the hypoxia pathway represents the major pathway involved in the genesis of the secondary erythrocytosis and VHL disease [13] [14] [15] 28 , we performed functional studies of the hypothetical wild-type or mutated X1 proteins using Hypoxia Response Element (HRE)-dependent reporter assays. These functional tests failed to reveal any substantial effects of X1 on this pathway, either alone or in competition with pVHL ( Figure 4C, Supplemental Fig.11 ). We next focused our study on a potential impact of the E1' variants on splicing by performing splicing reporter minigene assays in various cell lines. The experiments showed that splicing of the wild-type E1' is barely detected ( Figure 4D ). Interestingly, higher molecular weight bands corresponding to the expected spliced isoforms containing E1' appeared in the presence of the mutations. Cloning and sequencing of the isoforms confirmed a retention of E1' at the expected 1 2 splicing sites. The level of expression of the upper isoform, specific to E1' inclusion, was higher for mutations associated with cancers than for those with erythrocytosis, independently of the cell lines. Notably, the combination of both variants associated with cancer has a more pronounced effect than each variant individually (the SNP showing very low effect), suggesting a synergistic effect of the variants on splicing (Supplemental Fig.12) . In silico analysis of the c.340+617C>G
consistently predicted a severe alteration of splicing by the creation of an Exonic Splicing Enhancer (ESE) site (Supplemental Fig.13 ).
The minigene experiment performed with the mutated E1' at the SA site (F6) confirmed the inclusion of E1' during splicing ( Figure 4D , right panel), using the same dowstream alternative SA site identified in mRNA extracted from patients' LCL (Supplemental Fig.10 ).
Synonymous mutations in VHL-Exon 2 induce exon-skipping.
We then focused our study on the synonymous heterozygous D143D mutation in E2, identified in the proband of F1. This mutation was also identified in the homozygous state in two patients with erythrocytosis (F9, F10, Figure 5A , Table 1 Suspecting an effect of the synonymous mutations on splicing, we next assessed the expression of the VHL transcripts in patients' samples by RT-PCR ( Figure 5C ). We showed a significant change in the ratio of expressed VHL isoforms, with a higher expression of the E1-E3 transcripts in LCL of patients homozygous for D143D and in the pheochromocytomas with P138P mutation.
These results suggested an effect of the mutation on splicing regulatory elements, leading to E2
skipping. In silico analysis of the synonymous mutations indicated a potential effect on ExonicSplicing Enhancer (ESE) motifs (Supplemental Fig.14) .
In order to specifically quantify the different VHL isoforms, we performed quantitative RT-PCR on LCL using Taqman probes complementary to the VHL E1-E2 or E1-E3 junctions ( Figure 5D ).
All mutated samples displayed an increase of the isoform with skipped E2 (E1-E3). The patients carrying a homozygous D143D mutation presented a severe decrease of the wild-type isoform expression level. These results demonstrated that synonymous mutations in E2 affect mRNA isoform production.
In order to evaluate a potential impact on protein expression, we performed a western blot analysis. We did not observe any overexpression of the pVHL172 isoform as expected from mRNA quantification studies. However, in patients homozygous for D143D, we detected a strong downregulation of all the pVHL isoforms, which was also observed to a lesser extent in LCL samples from heterozygous patients ( Figure 5E ).
Proportion of VHL-E2 skipping is correlated to disease severity in minigene experiments.
In order to study the impact of the synonymous E2 mutations on splicing in different cell lines, we performed minigene assays. We tested the implications of the D143D and P138P mutations on splicing in addition to the nearby mutations described in patients with erythrocytosis (P138L and G144R). 4, 6, 29 Indeed, these mutations may also impact splicing rather than VHL protein function. We first evaluated the loss-of-function of these mutants by reporter assays. We showed that these could downregulate HIF in a manner similar to the wild-type protein, in contrast to VHL proteins lacking E2 (pVHLΔE2) which are described to be nonfunctional in terms of their regulation of HIF activity [8] [9] [10] 12 ( Figure 6A ). Minigene experiments were performed in a variety of cell lines relevant to the studied diseases, using LCLs as control ( Figure 6B ). We demonstrated that all mutations cause E2-skipping in LCLs. In other cell lines, these experiments demonstrated a major impact on the VHL-E2 splicing of the P138P mutation which is associated with cancer. The mutations P138L, D143D and G144R, which are all associated with erythrocytosis, displayed a weaker effect on splicing, with slight variations among cell lines but with a stronger effect in the erythroid cell line (UT7 cultured with EPO).
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Splicing dysregulation of VHL is causal in the developement of disease.
RNA-seq confirmed that the synonymous mutations were not silent but instead induce potent E2-skipping ( Figure 6C, Supplemental Fig.15A ). Further transcriptome analyses of the pheochromocytoma carrying P138P showed an upregulation of HIF target genes (typically seen in VHL-related pheochromocytomas) compared with the pheochromocytoma carrying a RET mutation (Supplemental Fig.15B ) 30 . We then re-analyzed our independent cohort of pheochromocytomas 30 using RNA-Seq data from both tumors. After unsupervised classification,
we observed a segregation of the P138P pheochromocytoma with other VHL related-tumors (C1B cluster) whereas the control pheochromocytoma bearing the RET mutation was grouped with other RET related-tumors ( Figure 6D ).
Discussion:
The hypoxia pathway plays a central role in erythrocytosis or tumors developed by patients carrying VHL mutations. Nevertheless, the full molecular mechanisms at the origin of these different phenotypes remain to be elucidated. To date, the functional studies of VHL mutants have been performed on missense mutations. We describe here, for the first time, functional studies of VHL mutations which do not have an impact on the coding sequence, but which influence the VHL splicing. We discovered a complex regulation of VHL splicing that may help to explain the complexity of genotype/phenotype correlations observed in VHL-related disorders. Notably, we demonstrated that synonymous variants (D143D or P138P) can have an impact on VHL splicing and should be considered as pathogenic mutations. Our study points to a particular region in the E2 that may be considered as a splicing regulatory domain. Therefore, it would be interesting to evaluate the impact of all the nucleotide changes described in VHL-E2 17 on splicing, in the same way as we described for two missense mutations (P138L, G144R). We observed that, depending on the mutation in this region, the impact on splicing can be moderate (D143D, G144R, P138L) or severe (P138P), which correlates with the severity of the disease seen in individuals carrying these VHL mutations (erythrocytosis versus cancers). This observation confirms the hypothesis of a continuum model of tumor suppression by VHL. 21, 31 Regarding the erythrocytosis developed in patients homozygous for D143D, both probands (F9 II.1 and F10 II.1) present mutations in the beta-globin gene (HBB) that induce hemoglobin 1 5 instability or thalassemia (Table 1) . This may compensate the strong erythropoiesis associated with a very high serum erythropoietin level associated with the D143D mutation.
More importantly, we discovered a new VHL cryptic-exon, E1', expressed in healthy tissues. Our study led to the identification of E1' heterozygous mutations occurring in the second allele of six families with an erythrocytosis previously associated with a heterozygous mutation in VHL rather than a homozygous mutation. Our investigations further confirmed that polycythemia associated with VHL mutation is definitely an autosomal recessive disease. In addition, we identified an E1' homozygous mutation in a patient with an erythrocytosis of unknown origin. This result demonstrates the causal role of the alteration in this new cryptic-exon in the pathophysiology of erythrocytosis. Importantly, we also identified E1' mutations in patients with unexplained VHL disease.
This VHL-E1' exon remained unidentified until this point because of its low expression and the fact that this deep intronic region was never explored or represented in WES data. Our data showed that these newly described E1'-containing transcripts may be polyadenylated (as they are captured by polydT in RNAseq) but are also likely to be subjected to NMD and may therefore fail to produce a protein. However, we cannot exclude the possibility that they are translated into a new protein (X1) not expressed in sufficient quantity to be detected by western blot. This potential X1 isoform would contain the VHL-E1 that encodes the NH2-terminal part of pVHL, including 16 residues involved in HIF binding from the 17 described. 26 Nonetheless, the hypoxiadependent reporter assays failed to identify a potential direct role of this isoform on the HIF pathway. Instead, our results provide compelling evidence that mutations in E1' induce a severe retention of this E1'cryptic-exon which correlates with a defect in global VHL protein expression. Therefore, our study strongly favors a dysregulation of splicing with a consequent downregulation of pVHL expression as the underlying cause of the diseases observed. Here, insufficient pVHL levels but not a reduced HIF binding by the mutant pVHL (as seen in the Chuvash polycythemia mutation VHL-R200W
may lead to an impairment of HIF degradation.
Of note is the fact that the functional study of mutations identified in E1' in association with erythrocytosis resulted in a less severe impact on splicing than the mutations associated with cancer, confirming that polycythemia is associated with VHL hypomorphic mutations.
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Our findings may have broad implications for patients with presumed congenital erythrocytosis.
First, the underlying cause of congenital erythrocytosis has been identified in only about one third of the patients in most published studies. However, previous studies have focused on missense and nonsense changes in coding regions and known regulatory domains of candidate genes. This has also been the case in patients with suspected VHL disease. Our study shows that synonymous exonic changes, as well as changes within intronic sequences affecting exon splicing, may be responsible for these disorders and should be considered during the diagnostic process. Notably, the VHL-E1' exon should be added in the list of regions routinely sequenced in patients with congenital erythrocytosis. Second, the detection of molecular changes has implications for the clinical management of patients. For example, phlebotomy in patients with VHL-or HIF2α-related erythrocytosis may even worsen the clinical situation by increasing the risk and severity of pulmonary hypertension in these patients. 32 Third, the confirmation of the continuum model of tumor suppression by VHL helps to understand the very low frequency of secondary tumors in patients with VHL-related erythrocytosis. 33 On the other hand, this also means that later occurrence of such neoplasms cannot be definitely excluded. Therefore, the clinical management of these patients should include regular follow-up to assess the risk for thromboembolic complications, pulmonary hypertension, and cardiovascular disease, as well as regular examinations to check for the presence of typical VHL-related tumors. Patients with VHL disease due to E1' mutations will also benefit from regular screening for tumors. Finally, the detection of these new genetic changes will also allow appropriate genetic counselling of affected patients and their families.
In conclusion, VHL is a major tumor suppressor gene that plays a pivotal role in the oxygensensing pathway which is involved in multiple physiological (e.g. angiogenesis, erythropoiesis) and pathological (e.g. cancer) processes. 
